TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3907641

Group type: EXPERIMENTAL
Intervention: 5,6-benzo-alpha-pyrone/troxerutin combination (Venalot Depot)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: benzarone
Number of subjects: 41
Study: 30709746

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 29735457

Group type: EXPERIMENTAL
Intervention: Phellodendron wet compress
Number of subjects: 600

Group type: COMPARATOR
Intervention: Magnesium sulfate solution wet compress
Number of subjects: 600
Study: 26881793

Group type: EXPERIMENTAL
Intervention: Nurse led case management intervention
Number of subjects: 12181

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 12181
Study: 26109202

Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy (SC)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (ASCT)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Overall survival post-ASCT
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Event-free survival (EFS)
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Post-ASCT EFS
Number of subjects: 619
Study: 23121272

Group type: EXPERIMENTAL
Intervention: Sumatriptan-naproxen combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Butalbital formulation
Number of subjects: 0
Study: 19502017

Group type: EXPERIMENTAL
Intervention: Low glycemic load (LGL) diet
Number of subjects: 202

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 202
Study: 18284462

Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 3320

Group type: EXPERIMENTAL
Intervention: Control of hypertension
Number of subjects: 3320

Group type: EXPERIMENTAL
Intervention: Monotherapy for hypertension
Number of subjects: 3320

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 3320
Study: 15918446

Group type: EXPERIMENTAL
Intervention: Xcoating coated condensed extra-corporeal circuit (CondECC)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fully heparin-coated CPB circuit (control)
Number of subjects: 22
Study: 12095495

Group type: EXPERIMENTAL
Intervention: Low-dose oral hormonal contraception (Cileste: 250 microg of norgestimat and 35 microg of ethinylestradiol; Marvelon: 150 microg of desogestrel and 30 microg of ethinylestradiol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cileste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marvelon
Number of subjects: 0
Study: 10068412

Group type: EXPERIMENTAL
Intervention: Bedtime insulin plus metformin (2 g)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bedtime insulin plus glyburide
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bedtime insulin plus both oral drugs (glyburide and metformin)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bedtime and morning insulin
Number of subjects: 96
Study: 7985893

Group type: EXPERIMENTAL
Intervention: Ceredase (alglucerase) infused every 2 weeks for 9 months at a dose of 60 U/kg body weight
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cerezyme (imiglucerase) infused every 2 weeks for 9 months at a dose of 60 U/kg body weight
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ceredase
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cerezyme
Number of subjects: 30
Study: 2974416

Group type: EXPERIMENTAL
Intervention: Tiapride
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30353773

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation programme (1-hour sessions weekly for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group (relaxation techniques weekly for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 29631820

Group type: EXPERIMENTAL
Intervention: Standard-of-care preappointment information plus estimated appointment wait time
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard-of-care preappointment information
Number of subjects: 50
Study: 28797857

Group type: EXPERIMENTAL
Intervention: Comfort care
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Basic care
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Intensive medical care
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Proxy perception of resident having less than six months to live
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Older resident age
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Worse resident cognitive impairment
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Proxy asked about goals of care preferences by NH health care provider
Number of subjects: 402
Study: 26238287

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement
Number of subjects: 699
Study: 24216675

Group type: EXPERIMENTAL
Intervention: 5‐aminolevulinic acid‐mediated photodynamic therapy (ALA‐PDT) for lesions <0.5 cm
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: ALA‐PDT plus cryotherapy for lesions 0.5‐2.0 cm
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: ALA‐PDT retreatment after cryotherapy or CO2 laser treatment for lesions >2.0‐4.0 cm
Number of subjects: 361
Study: 21446870

Group type: EXPERIMENTAL
Intervention: Damon system
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (conventionally ligated edgewise bracket system)
Number of subjects: 27
Study: 18317189

Group type: EXPERIMENTAL
Intervention: Multifaceted guideline implementation (GI)
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Multifaceted guideline implementation plus training of practice nurses in motivational counseling (MC)
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Postal dissemination of the guideline (controls)
Number of subjects: 1378
Study: 21395626

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus IMC 501® and Lactobacillus paracasei IMC 502®)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 50
Study: 16120070

Group type: EXPERIMENTAL
Intervention: Concomitant use of analgesics and psychotropics
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Concomitant use of psychotropics and opioids
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Use of opioids among concomitant users
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Concomitant users of analgesics
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Concomitant users
Number of subjects: 523
Study: 12399278

Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation (500 micro g)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Phylloquinone supplementation (1000 micro g)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Phylloquinone supplementation (250 micro g)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Phylloquinone supplementation (375 micro g)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 9756471

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN) therapy at a daily dose of 5 million international units
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN) therapy at a daily dose of 10 million international units
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN) therapy at a daily dose of 15 million international units
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b (IFN) therapy
Number of subjects: 23
Study: 8167575

Group type: EXPERIMENTAL
Intervention: Special Care Unit (SCU)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional integrated units
Number of subjects: 22
Study: 3168620

Group type: EXPERIMENTAL
Intervention: Medium intervention
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low intervention
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 10
Study: 12185890

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31876197

Group type: EXPERIMENTAL
Intervention: Dydrogesterone supplementation (30 mg/d)
Number of subjects: 406
Study: 30178335

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 12

Group type: COMPARATOR
Intervention: Upright position
Number of subjects: 12
Study: 27339759

Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 946

Group type: COMPARATOR
Intervention: COC
Number of subjects: 946
Study: 25434316

Group type: EXPERIMENTAL
Intervention: Gum chewing (sugarless gum, half an hour three times daily after meals for 3 days)
Number of subjects: 129

Group type: COMPARATOR
Intervention: High-dose senna (150 mL senna solution, 300 mg senna the night before colonoscopy and 80 mg sennoside tablet daily for 3 days)
Number of subjects: 129
Study: 22392169

Group type: EXPERIMENTAL
Intervention: Expressed breast milk (EBM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: 25% glucose (control group)
Number of subjects: 113
Study: 20938039

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin daily for 12 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 162.5 mg aspirin daily for 12 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 325 mg aspirin daily for 12 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 650 mg aspirin daily for 12 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 1300 mg aspirin daily for 12 weeks
Number of subjects: 70
Study: 18726812

Group type: EXPERIMENTAL
Intervention: MyStudentBody-Stress
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control health information website
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 15613583

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12402052

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel hemorrhoidectomy (HS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Milligan‐Morgan procedure (MM)
Number of subjects: 54
Study: 10433671

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Plain liquid soap
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 70% ethyl alcohol
Number of subjects: 5
Study: 7607751

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ramipril and enalapril)
Number of subjects: 7
Study: 2222157

Group type: EXPERIMENTAL
Intervention: Manual stretch of extrinsic finger flexor muscles
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no manual stretch)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Experimental group (manual stretch)
Number of subjects: 16
Study: 364010

Group type: EXPERIMENTAL
Intervention: Fluoride solution and/or silver nitrate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment or placebo
Number of subjects: 0
Study: 31130215

Group type: EXPERIMENTAL
Intervention: Machine Learning models (ANN, SVM, Naïve Bayes) using computed IVUS features
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Machine Learning models (ANN, Naïve Bayes) in the test set
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: IVUS sections with OCT-TCFA
Number of subjects: 517

Group type: COMPARATOR
Intervention: IVUS sections without OCT-TCFA
Number of subjects: 517
Study: 28767333

Group type: EXPERIMENTAL
Intervention: 10-session version of GPM augmented with MOTR
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10-session version of GPM (control group)
Number of subjects: 50
Study: 25266357

Group type: EXPERIMENTAL
Intervention: Bladder training + pelvic floor muscle training (BT + PFMT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Bladder training (BT)
Number of subjects: 108
Study: 23812136

Group type: EXPERIMENTAL
Intervention: Preoperative bowel preparation (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No bowel preparation (group B)
Number of subjects: 60
Study: 20523301

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet for 12 weeks
Number of subjects: 78
Study: 19548447

Group type: EXPERIMENTAL
Intervention: Combination of ganji recipe and Fructus Bruceae oil emulsion (FBE)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Trans‐hepatic arterial chemical embolization (TACE) alone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combination of ganji recipe and FBE
Number of subjects: 77

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 77
Study: 16910066

Group type: EXPERIMENTAL
Intervention: 1.5 grams of second generation cephalosporin (cefuroxime sodium) diluted in 100ml of normal saline at the time of induction of anesthesia (Group A)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Normal saline only (Group B)
Number of subjects: 93
Study: 12765457

Group type: EXPERIMENTAL
Intervention: Dual chamber pacing
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Atrial-based pacing
Number of subjects: 6000
Study: 10639031

Group type: EXPERIMENTAL
Intervention: BR21 (0.5, 1.0, 1.5, 2.0, and 2.5 mL/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0.9% saline, 10 volunteers)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BR21
Number of subjects: 30
Study: 8940985

Group type: EXPERIMENTAL
Intervention: Transfusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Normal saline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resuscitation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Treatment for metabolic acidosis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fluid replacement
Number of subjects: 24
Study: 1537519

Group type: EXPERIMENTAL
Intervention: 500 mg chenodeoxycholic acid (CDCA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 250 mg UDCA
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 500 mg UDCA
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1000 mg UDCA
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 2000 mg UDCA
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control period (no UDCA administration)
Number of subjects: 6
Study: 6375710

Group type: EXPERIMENTAL
Intervention: Combination tablet of pindolol 10 mg and clopamide 5 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Separate tablets of pindolol 10 mg and clopamide 5 mg
Number of subjects: 160
Study: 31165854

Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemo-endocrine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oncotype DX testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial care costs posttrial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy for women aged 50 years and younger with RS 16-25
Number of subjects: 0
Study: 29141505

Group type: EXPERIMENTAL
Intervention: Gluten-free diet with zinc supplements (GFD +Zn)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Gluten-free diet (GFD)
Number of subjects: 71
Study: 27621440

Group type: EXPERIMENTAL
Intervention: Treatment that framed healthy eating as consistent with adolescent values of autonomy and social justice
Number of subjects: 536

Group type: COMPARATOR
Intervention: Traditional health education materials
Number of subjects: 536

Group type: COMPARATOR
Intervention: Non-food-related control
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Treatment that framed healthy eating as consistent with adolescent values
Number of subjects: 536
Study: 23721647

Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus ω‐3 supplementation (EPA + DHA, 3 g/d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Scaling and root planing plus placebo
Number of subjects: 10
Study: 22776871

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen twice before cycling
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cycling without ibuprofen
Number of subjects: 9

Group type: COMPARATOR
Intervention: 400 mg ibuprofen twice at rest
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rest without ibuprofen intake
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cycling with ibuprofen
Number of subjects: 9

Group type: COMPARATOR
Intervention: 400 mg ibuprofen at rest
Number of subjects: 9

Group type: COMPARATOR
Intervention: Rest without ibuprofen
Number of subjects: 9
Study: 21046504

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 174
Study: 17609332

Group type: COMPARATOR
Intervention: Random practice order in control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blocked practice order in control group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blocked practice order in PD group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Random practice order in PD group
Number of subjects: 40
Study: 15625158

Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine 75 mg daily for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12119210

Group type: EXPERIMENTAL
Intervention: Community-based education program (8 classes in 1 year)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Community-based education program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (2 classes)
Number of subjects: 104
Study: 9710040

Group type: EXPERIMENTAL
Intervention: rhIGF‐I 0.1 mg/kg/day subcutaneously for 9 months
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 7480965

Group type: EXPERIMENTAL
Intervention: Doxazosin (2 mg orally)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 18
Study: 2470569

Group type: EXPERIMENTAL
Intervention: Iloprost (2 ng/kg.min over six hours for 28 consecutive days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (saline infusion for 28 consecutive days)
Number of subjects: 101
Study: 53719

Group type: EXPERIMENTAL
Intervention: Intramuscular insulin (small doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of insulin (small doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Large intravenous boluses of insulin (control)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Potassium requirements during treatment (both groups)
Number of subjects: 36
Study: 30868497

Group type: EXPERIMENTAL
Intervention: Intramuscular parecoxib (40 mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: 1% tetracaine gel (control group)
Number of subjects: 101
Study: 28957887

Group type: EXPERIMENTAL
Intervention: Ketamine-propofol-midazolam (KPM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fentanyl-propofol-midazolam (FPM)
Number of subjects: 80
Study: 23689964

Group type: EXPERIMENTAL
Intervention: Arthroscopic transtendon repair
Number of subjects: 74

Group type: COMPARATOR
Intervention: Arthroscopic completion of the tear and formal repair
Number of subjects: 74
Study: 25111121

Group type: EXPERIMENTAL
Intervention: Sucrose (SUC) or high fructose corn syrup (HFCS) in low-fat milk at 8%, 18% or 30% of calories
Number of subjects: 355
Study: 22981146

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 to 80 mg for 42 days (dyslipidemic patients)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg for 21 days (non-patient volunteers)
Number of subjects: 26
Study: 18971794

Group type: EXPERIMENTAL
Intervention: Estradiol gel 0.1% (1.0 mg/day)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Estradiol gel 0.1% (0.5 mg/day)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Estradiol gel 0.1% (0.25 mg/day)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Estradiol gel 0.1% (1.0, 0.5, and 0.25 mg/day)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488
Study: 17825656

Group type: EXPERIMENTAL
Intervention: Elective cesarean delivery
Number of subjects: 0
Study: 14762749

Group type: EXPERIMENTAL
Intervention: Wire osteosynthesis and maxillomandibular fixation for 6 weeks (Group 1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Rigid internal fixation (Group 2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 37
Study: 11133633

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg IV before spinal anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study: 9625823

Group type: EXPERIMENTAL
Intervention: PCNA labeling index in lung metastasis group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PCNA labeling index in primary lesions of lung metastasis group
Number of subjects: 26

Group type: COMPARATOR
Intervention: PCNA labeling index in no metastasis group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CEA distribution patterns
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CA19-9 staining patterns
Number of subjects: 26
Study: 8143396

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Warfarin and Etodolac
Number of subjects: 18
Study: 3144441

Group type: EXPERIMENTAL
Intervention: alfentanil (15 micrograms.kg‐1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: fentanyl (1.5 microgram.kg‐1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: enflurane
Number of subjects: 59
Study: 2147834

Group type: EXPERIMENTAL
Intervention: Enoximone (3.6 mg/kg total dose over 3 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dobutamine (10 micrograms/kg/min for 30 minutes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 20
Study: 1097343

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxycycline or Minocycline
Number of subjects: 0
Study: 31558359

Group type: EXPERIMENTAL
Intervention: High dynamic sports
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High dynamic and static sports
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Microbial metabolites (faecal) and human metabolites (urine)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Dietary intake
Number of subjects: 37
Study: 30151651

Group type: EXPERIMENTAL
Intervention: Shared Decision-Making using Routine Outcome Monitoring (SDMR)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Decision-Making As Usual (DMAU)
Number of subjects: 186